Building the nation’s capacity to conduct pragmatic clinical trials embedded within healthcare systems for people living with dementia and their care partners
Jason Karlawish, MD, leader of the IMPACT Collaboratory Regulatory and Ethics Core, was quoted in a December 20th New York Times article, “Alzheimer’s Tests Soon May Be Common. Should You Get One? Diagnostic tests for Alzheimer’s disease are already here. But the results may raise as many questions as they answer.”
Keith Goldfeld, DrPH, MS, MPA, member of the IMPACT Collaboratory Design and Statistics Core Executive Committee wrote a blog post about the network and how it can help with pragmatic pilot studies to investigate promising interventions for people living with Alzheimer’s disease and related dementias.
Goldfeld shares what we can expect to learn from a relatively small pilot study of a new intervention. The blog shares two articles addressing small pilot studies, and provides simulations to see how a small pilot study could potentially lead to poor design decisions with respect to sample size. Read the full post on Goldfeld’s blog here.
December 2019 – In Grand Rounds 2, Dr. Taljaard describes the use of stepped wedge design in cluster randomized trials (SW-CRT), a novel research design embraced by clinical researchers.
Kasza J1, Taljaard M2,3, Forbes AB1 Information content of stepped-wedge designs when treatment effect heterogeneity and/or implementation periods are present https://www.ncbi.nlm.nih.gov/pubmed/31321806